Vertex Pharmaceuticals
Q1 2022 Earnings Call
May 05, 2022, 4:30 p.m. ET
Contents:
- Prepared Remarks
- Questions and Answers
- Call Participants
Prepared Remarks:
Michael Partridge
Good evening. This is Michael Partridge. Welcome to Vertex's first quarter 2022 financial results conference call. On tonight's call, making prepared remarks, we have Dr.
Reshma Kewalramani, Vertex's CEO and president; Stuart Arbuckle, chief operating officer; and Charlie Wagner, chief financial officer. Dr. Bastiano Sanna, chief of Vertex Cell and Genetic Therapies; and Dr. David Altshuler, chief scientific officer, will join for Q&A.
We recommend that you access the webcast slides as you listen to this call. This call is being recorded, and a replay will be available on our website. We will make forward-looking statements on this call that are subject to the risks and uncertainties discussed in detail in today's press release and in our filings with the Securities and Exchange Commission. These statements, including, without limitation, those regarding Vertex's marketed CF medicines, our pipeline, and Vertex's future financial performance are based on management's current assumptions.
Actual outcomes and events could differ materially. I would also note that select financial results and guidance we will review on the call this evening are non-GAAP. I will now turn the call over to Dr. Reshma Kewalramani.
Reshma Kewalramani -- Chief Executive Officer and President
Thanks, Michael. Before we begin, as this will be Michael Partridge's last quarterly call with us, I'd like to take a moment to recognize Michael for his outstanding service and contributions to Vertex. For 25 years, he has been the face of Vertex with analysts and investors, and with his calm and steady approach, Michael has led our IR team through countless milestones and many evolutions of the company. More recently, through the launch of all four of our marketed cystic fibrosis medicines and the emergence of our broad, mid- and late-stage pipeline, Michael has been an integral part of the Vertex leadership team, helping share our story with the world.
Michael has shown a true passion for Vertex and the patients we serve. We are grateful for his dedication, and I want to personally thank Michael for all that he's done for Vertex. On to the quarterly review. Vertex is off to an excellent start across the board with strong performance in the CF business, rapid advancement of the pipeline, and continued operational excellence.